topic

1075 Development of WTX-712, a conditionally active IL-21 INDUKINE^TM molecule for the treatment of cancer
Jenna M Sullivan, Pam Aderhold, Heather R Brodkin, Celesztina Nagy-Domonkos, Kyriakos Economides, Daniel J Hicklin, Nesreen Ismail, Cynthia Seidel-Dugan, William M Winston, Andres Salmeron

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1184; DOI: 10.1136/jitc-2023-SITC2023.1075
1076 Discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity
Deborah A Witherden, Eric K Elliott, Christine M Chidester, Maggie S Willen, Bryan R Peguero, Merrick Chai, Robert A Horlick, David J King, H Toni Jun

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1185; DOI: 10.1136/jitc-2023-SITC2023.1076
1077 Preclinical and IND-enabling studies of TXN10128, an ENPP1 inhibitor, for clinical evaluation in patients with solid tumor
Shin-Yeong Kim, Sun Woo Lee, Hye Lim Choi, Jun Yong Choi, Hyang Ji Chae, Eun Kyung Yoo, Chang Won Min, Junghwan Choi, Bo Kyung Sun, Eun Young Kwak, Yongyea Park, Sungjoon Kim, JongRan Kim, Jong Heun Lee, Chan Sun Park

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1186; DOI: 10.1136/jitc-2023-SITC2023.1077
1078 Agonistic CD40 IgM antibodies enhance immune responses beyond that of IgGs
Sarang Tartey, Vignesh Narayanaswamy, Deepal Pandya, Vidhya Bai Krishnoji Rao, Elizabeth Perez, Paul Hinton, Dean Ng, Umesh Muchhal, Bruce Keyt, Angus Sinclair, Hyewon Phee

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1187; DOI: 10.1136/jitc-2023-SITC2023.1078
1079 Type I interferon regulation by USP18 is a key vulnerability in cancer
Veronica Jove, Heather Wheeler, Chiachin Wilson Lee, David R Healy, Kymberly Levine, Erik C Ralph, Bing Yang, Anand Giddabasappa, Paula Loria, Masaya Yamaguchi, Agustin Casimiro-Garcia, Benedikt M Kessler, Adan Pinto-Fernandez, Veronique Frattini, Feng Wang, Paul Wes

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1188; DOI: 10.1136/jitc-2023-SITC2023.1079
1080 Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages
Tal Kan, Yiftah Barsheshet, Boris Brant, Tharwat Haj Khalil, Tali Voloshin, Alexandra Volodin, Lilach Koren, Bella Koltun, Anat Klein-Goldberg, Efrat Zemer-Tov, Rom Paz, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1189; DOI: 10.1136/jitc-2023-SITC2023.1080
1081 CD25-specific aptamer conjugated with cytotoxic payloads shows the potential to modulate immune-suppressive environment in tumors by depleting Tregs selectively
Daekyun Lee, Ju-hyung Kang, Inu Song

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1190; DOI: 10.1136/jitc-2023-SITC2023.1081
1082 Enhancing NK cell-mediated anti-tumor activity through modulation of TIM-3
Yuning Liu, Sandro Matosevic

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1191; DOI: 10.1136/jitc-2023-SITC2023.1082
1083 Functional impact of adrenergic signaling on T and NK cells: where exercise meets cancer
Thy V Luu, Agnete WP Jensen, Gitte H Olofsson, Per thor Straten

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1192; DOI: 10.1136/jitc-2023-SITC2023.1083
1084 Local administration of large surface area microparticle docetaxel is associated with anti-tumor immunomodulation across multiple tumor types
Holly A Maulhardt, Alyson M Marin, Marc A Iacobucci

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1193; DOI: 10.1136/jitc-2023-SITC2023.1084

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages